DiaMedica Therapeutics (DMAC) EBITDA Margin (2018)
DiaMedica Therapeutics' (DMAC) quarterly EBITDA Margin came in at 297.4% in Q3 2018.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) EBITDA Margin (2018) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported EBITDA Margin for 1 consecutive years, with 297.4% the latest figure, recorded in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.17 Bn | 193.18 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.74 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.28 Bn | 48.14 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | -25,380.93% |
| 10 | DiaMedica Therapeutics | 346.54 Mn | 346.54 Mn | - | - |